Application Methods: Western Blotting
Background: Ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP1) is a single-pass, type II transmembrane protein primarily involved in ATP hydrolysis at the plasma membrane. Targeting of ENPP1 to the basolateral cell surface relies on the presence of a carboxy-terminal di-leucine-based signal (1). ENPP1 plays important roles in bone mineralization and soft tissue calcification (2-5). Mutations in the corresponding ENPP1 gene cause generalized arterial calcification in infancy (GACI) and idiopathic infantile arterial calcification (IIAC) (6,7). ENPP1 inhibits insulin receptor function and overexpression of this enzyme causes insulin resistance and glucose intolerance in mice (8,9). Genetic variants of ENPP1 have been associated with obesity and type 2 diabetes (10-12).
Application Methods: Immunohistochemistry (Paraffin), Western Blotting
Background: Ectonucleoside triphosphate diphosphohydrolase 1 (NTPDase 1, also known as CD39) is a multi-pass membrane ectoenzyme that metabolizes adenosine tri-phosphate (ATP) to regulate purinergic signaling. Purinergic signaling by extracellular ATP and its metabolites regulate many biological processes, including vascular tone, digestion, neuronal function, and inflammation in both normal and diseased states (1). NTPDase 1 is expressed in endothelial cells in the vasculature to regulate local platelet purinergic signaling via metabolism of ATP to adenosine (2). Accordingly, NTPDase 1 regulates platelet activation aggregation and contributes to the antithrombotic properties of endothelial cells (3). ATP and its metabolites also finely modulate the activity of T cells and macrophages (4, 5). Immunomodulation is regulated, in part, by the availability of extracellular ATP and adenosine, suggesting that NTPdase 1 (CD39) may play an immunosuppressive role in the tumor microenvironment.